Galapagos NV
AEX:GLPG

Watchlist Manager
Galapagos NV Logo
Galapagos NV
AEX:GLPG
Watchlist
Price: 25.84 EUR -0.84% Market Closed
Market Cap: 1.7B EUR
Have any thoughts about
Galapagos NV?
Write Note

Galapagos NV
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Galapagos NV
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Galapagos NV
AEX:GLPG
Accounts Receivables
€60m
CAGR 3-Years
-16%
CAGR 5-Years
13%
CAGR 10-Years
N/A
M
MDxHealth SA
NASDAQ:MDXH
Accounts Receivables
$13.5m
CAGR 3-Years
46%
CAGR 5-Years
-6%
CAGR 10-Years
12%
Oxurion NV
XBRU:OXUR
Accounts Receivables
€316k
CAGR 3-Years
-23%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
Celyad Oncology SA
XBRU:CYAD
Accounts Receivables
€380k
CAGR 3-Years
24%
CAGR 5-Years
10%
CAGR 10-Years
N/A
No Stocks Found

Galapagos NV
Glance View

Market Cap
1.7B EUR
Industry
Biotechnology

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 1,309 full-time employees. The company went IPO on 2005-05-06. The firm is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

GLPG Intrinsic Value
28.4 EUR
Undervaluation 9%
Intrinsic Value
Price

See Also

What is Galapagos NV's Accounts Receivables?
Accounts Receivables
60m EUR

Based on the financial report for Sep 30, 2024, Galapagos NV's Accounts Receivables amounts to 60m EUR.

What is Galapagos NV's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
13%

Over the last year, the Accounts Receivables growth was 28%. The average annual Accounts Receivables growth rates for Galapagos NV have been -16% over the past three years , 13% over the past five years .

Back to Top